CStone Pharmaceuticals
HKEX:2616
Net Margin
CStone Pharmaceuticals
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | CN |
Market Cap | 1.7B HKD |
Net Margin |
-79%
|
Country | US |
Market Cap | 293.9B USD |
Net Margin |
11%
|
Country | US |
Market Cap | 167.6B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 115B USD |
Net Margin |
39%
|
Country | US |
Market Cap | 108.2B USD |
Net Margin |
29%
|
Country | AU |
Market Cap | 135.3B AUD |
Net Margin |
17%
|
Country | US |
Market Cap | 84.4B USD |
Net Margin |
2%
|
Country | US |
Market Cap | 50.9B USD |
Net Margin |
-116%
|
Country | US |
Market Cap | 43.1B USD |
Net Margin |
-33%
|
Country | US |
Market Cap | 33.6B USD |
Net Margin |
12%
|
Country | KR |
Market Cap | 39.7T KRW |
Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for CStone Pharmaceuticals.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CStone Pharmaceuticals's most recent financial statements, the company has Net Margin of -79.2%.